The degree of drug-induced neutropenia resulting from a controlled trial (UKALL I) of treatment in acute lymphoblastic leukaemia was analysed. The main agent associated with severe neutropenia was methotrexate, and methotrexate-induced neutropenia was significantly greater in patients who had received craniospinal irradiation. The synergistic toxic effect of irradiation followed by methotrexate treatment seems to have contributed to three of the five deaths which occurred in complete remission in this trial; all deaths in remission occurred in patients who had received central nervous system prophylaxis. Analysis of patients who subsequently relapsed compared with those still in remission after 18 months of treatment indicated that the former, on average, had slightly lower neutrophil counts. This suggests that the children who relapsed did not receive any less aggressive treatment than those who remained in remission.
Introduction
Combination chemotherapy in acute lymphoblastic leukaemia has greatly reduced the rate of haematological relapse. In the absence of specific preventive measures, however, a high proportion of patients with this disease relapse with central nervous system (C.N.S.) involvement.'-3 The Memphis group pionereed successful C.N.S. prophylactic treatment and found that craniospinal irradiation greatly reduced the incidence of this complication.4 Subsequently the British Medical Research Council undertook a controlled trial (UKALL I) to confirm the Memphis observation. In the first 18 months of this trial it was shown that while 26 out of 80 patients not receiving C.N.S.
prophylaxis relapsed with C.N.S. leukaemia only one of the 75 receiving prophylaxis primarily relapsed with this complication. 5 On the other hand, while none of the non-irradiated patients died in complete remission five such deaths occurred in the C.N.S. prophylaxis group. We have reported the considerable difference in lymphocyte counts between these groups and analysed the types of lymphocytes depleted 84 weeks after entry to the trial.6 At 84 weeks there was no apparent difference in neutrophil counts, but analysis of the deaths in remission showed that three out of four patients with available counts had pronounced neutropenia at the time of death. In this report we show that neutropenia is much more pronounced at certain stages of UKALL I maintenance chemotherapy than at others and that C.N.S. irradiation predisposes to drug-induced neutropenia for at least 18 months.
The Trial
The trial protocols are summarized in fig. 1 . All methotrexate courses were of five daily doses except for the first two at 15 and 17 weeks, which were of three and four doses respectively. After week 24 12-week cycles as given between weeks 13 and 24 (but with full fiveday courses of methotrexate) were administered. There were only two differences between the drug schedules for the two groups. Firstly, patients not receiving C.N.S. prophylaxis were given an extra five-day course of cytarabine during week 9. Secondly, and, more importantly, in each of the 11 methotrexate courses between weeks 17 and 55 the C.N.S. prophylaxis group received the first dose of methotrexate intrathecally. The main analysis in this study continues to the end of week 84, when patients were divided into subgroups receiving continued chemotherapy, no chemotherapy, or immunotherapy without chemotherapy.
The radiation was applied to the cranium to a total midline dose of 2500 rads by opposing lateral fields, which at most centres included the posterior part of the orbit. The apparatus used was not constant and included supervoltage, 250 kV, and cobalt sources. The cranial irradiation was usually completed within two and a half weeks but was sometimes protracted by another week or so mostly on account of myelodepression. During the second half of this time spinal irradiation to a total dose of 1000 rads (measured at the posterior surface of the vertebral bodies) was also given.
Because This gives a far better indication of the incidence of neutropenia than the mean, which is complicated by reactive neutrophilia. This cut-off point was arbitrally chosen.
Results

MEAN NEUTROPHIL COUNTS
The values for both groups for the first four cycles of maintenance chemotherapy are plotted in fig. 2 . The most striking point was the gross variation in counts in both groups during the cycle. The lowest counts were seen in the weeks after courses of methotrexate. There was some recovery before the next course, which continued during the course of continuous mercaptopurine. There was slightly greater neutropenia immediately after methotrexate courses in the irradiated group with a corresponding tendency to a greater rate of recovery in the ensuing nine-day period off treatment. This tendency to greater fluctuation in the irradiated group was consistent with the experimental observations of Morley et al.,8 who showed that colony stimulating factor levels in the sera of irradiated mice were directly related to the degree of neutropenia induced. Counts did, however, tend to fall slightly in the last week of mercaptopurine treatment. The highest counts were consistently seen during the two weeks when prednisolone and vincristine were given. This rise did not represent true recovery of neutrophils but mobilization of these cells into the blood as a result of the prednisolone. This is well illustrated by looking at counts after 85 weeks, when some patients stopped chemotherapy. In the group receiving prednisolone during weeks 85 and 86 there was a pronounced rise in mean neutrophil count while the patients stopping chemotherapy showed no such rise. This rise was highly significant (P<0-001; Wilcoxon non-parametric test).
The rise in neutrophil counts after the first week's prednisolone treatment was consistently greater in the non-prophylaxis group, but only significantly greater in weeks 14 and 26-that is, during the first two cycles after irradiation. In the week after each methotrexate course mean neutrophil counts were more depressed in the irradiated group. The log neutrophil counts of the irradiated patients were significantly lower than those of the non-irradiated patients after 10 of the first 18 methotrexate courses (P <0 05; two-tailed t test).
PROPORTION OF PATIENTS WITH BLOOD NEUTROPHIL COUNTS BELOW
To test the incidence of significant neutropenia the number of patients with neutrophil counts below 1 x 109/1 was determined. Fig. 3 plots the percentage of patients in each group with counts below this level during the first six cycles of maintenance chemotherapy. The differences between the C.N.S. prophylaxis group and the non-irradiated group after methotrexate courses were obvious. After 16 of the 18 courses of methotrexate the proportion of patients with neutrophil counts below 1 x 109/1 was greater in the prophylaxis group. The significance of this difference was assessed by scoring, for each patient, the proportion of observations after methotrexate courses in which neutrophil counts were below 1 x 109/1. Any patient with fewer than half the mean number of recorded observations was excluded from the analysis. The average score for the irradiated group was 0-278 (n= 51) compared with 0 129 (n = 63) for the non-irradiated group. The difference between the groups was assessed using a finite population correction factor, as in Armitage;9 the significance of the difference between the groups was P <0 001.
Apart from C.N.S. irradiation, the C.N.S. prophylaxis group also received the first dose of each methotrexate course from week 18 to week 56 by intrathecal injection. This might have been partly responsible for the increased methotrexate-associated neutropenia in the C.N.S. prophylaxis group, but the proportion of patients with The neutrophil counts in each patient were analysed to see if episodes of pronounced neutropenia were characteristic of individuals who consistently had neutrophil counts below the mean. No such pattern was apparent and the counts of several patients with counts generally above average were seen to drop acutely to below 0 5 x 109/1. If a patient had had one episode of profound neutropenia this would not necessarily be repeated in subsequent cycles though it might be.
CORRELATION OF NEUTROPENIA WITH CLINICALLY OBSERVED TOXIC EFFECTS
Remission Deaths.-All five deaths in complete remission were confined to the C.N.S. prophylaxis group (see table) . Four of the deaths were associated with acute terminal episodes. Three of these had recorded profound neutropenia, while in the fourth case, in which the child was admitted moribund, no count was available. Three of these acute episodes occurred during a week after methotrexate administration ( fig. 3 ). The fourth, however, showed an atypical myeloid depression associated with both mercaptopurine and vincristine. Vincristine-induced myelotoxicity was difficult to analyse in this trial because this drug was always given with prednisolone. Nevertheless, counts below 1 109ll were seen in every cycle in both groups after the injections of vincristine. The fifth death was not associated with neutropenia or lymphopenia and followed repeated gradual fits from the end of the fourth cycle. No antileukaemic treatment was given for 19 days before death in status epilepticus. The cerebrospinal fluid examination was uninformative in this case but brain sections at necropsy were suggestive of viral encephalitis and measles virus inclusions were shown. Relapse.-It could be argued that deaths in remission are justifiable consequences of aggressive treatment if it can be shown that only by pushing patients to the limits of toxicity can good long-term survival be achieved. To test this hypothesis patients in the C.N.S. prophylaxis group were analysed in two further groups: those relapsing before 84 weeks and those still in remission at 84 weeks. For this purpose counts in the month immediately before relapse were not included. The mean neutrophil counts in these two groups are recorded in fig. 4 . The numbers in the relapse group were small but the data indicate that there was no evidence of inadequate treatment in this group. 
Discussion
It is tempting to conclude that neutropenia was the main cause of death in four of the five remission fatalities in this trial. As over a quarter of all the patients in the C.N. second paper in this series, which compares neutropenia in UKALL I with that in the second UKALL trial. In UKALL II methotrexate was given in the same overall dosage as UKALL I but in different relationship to mercaptopurine, vincristine, and prednisolone. The schedule in UKALL II, despite essentially the same craniospinal prophylaxis, caused significantly less neutropenia. The same point can be made from the data in this study in that methotrexate is considerably more myelotoxic after previous craniospinal irradiation, even if irradiation is given more than one year before.
The type of fatal infection during remission described in this study is, in general, unlike the serious episodes of infection described by the Memphis group.4 1213 They state that "Nonbacterial micro-organisms, particularly Pneumocystis carinii and viruses" caused most of their infections. Maintenance treatment in those trials included continuous daily mercaptopurine and weekly methotrexate; C.N.S. prophylaxis was essentially the same as that given in UKALL I. The infections in the second UKALL trial, reported in the next paper in this series, fit more closely the pattern described by the Memphis group. Again, this emphasizes that relatively minor changes in timing of drug administration can result in a totally altered pattern of immunosuppression and myelosuppression and, therefore, drug toxicity while retaining similar antileukaemic activity.
The long-lasting effect of craniospinal irradiation is striking when one recalls that much of the red marrow was not irradiated. The iliac, femoral, and much of the costal marrow will have received only slight scatter exposure. Several points arise from these observations for discussion: how readily can myeloid stem cells move from one part of the body to another ? If there is free movement of stem cells why does complete reconstitution not occur from non-irradiated sites ? It is possible that repopulation occurs too rapidly. Because irradiation is given in several fractions, stem cells repopulating irradiated marrow after early exposure would be susceptible to damage by subsequent doses of irradiation. This sort of effect is well recognized in relation to recirculating lymphocytes. For instance, Fordl4 has shown that a short-range p-emitting strip placed on a rat spleen can eventually result in gross depletion of the recirculating pool of lymphocytes, as the spleen is a traffic organ for these cells.
Another possible explanation for the longevity of increased susceptibility to methotrexate-induced neutropenia is that irradiation destroys the capacity of bone cavities to support active red marrow. Even if this were so it seems an unlikely explanation for the spleen, liver, and fatty marrow of long bones are known to be reserve sites of myelopoiesis and haemopoiesis. Irradiated marrow could conceivably produce an abscopal effect on distant marrow, as, for instance, a kidney perfused through a stenosed renal artery induces hypertension that damages the contralateral organ. Finally, perhaps the most likely explanation for this long-term effect of irradiation is that maintenance chemotherapy simply prevents or greatly slows myeloid recovery after irradiation damage. In this way a normally short-lived reduction in myeloid capacity could become protracted over many months.
Introduction
The clinical observation of altered sensitivity to digitalis in patients with thyroid disease has been attributed to a change of intrinsic myocardial function which modifies its response to digitalis, as shown in isolated muscle strip preparations,' 2 animals,3 and man.4 In addition, isotopic studies using singledose tritiated digoxin5 and digitoxin or ouabain6 have shown lower serum levels in hyperthyroidism and higher levels in hypothyroidism. Doherty and Perkins found no significant difference in either digoxin excretion or serum half times and postulated an increased tissue distribution as a possible cause of the low serum levels in hyperthyroid patients. 5 Our aim was to reassess the influence of renal function on serum digoxin levels in patients with thyroid disease using radioimmunoassay for measurement of serum and urinary digoxin.
Patients and Methods
Studies were performed in 17 hyperthyroid and 16 hypothyroid patients with moderate to severe disease. There were two men in each group. Twenty-four of the 33 studies were performed on hospital
